ISSN:
1432-2072
Keywords:
Schizophrenia
;
Antipsychotics
;
Dopamine
;
Raclopride
Source:
Springer Online Journal Archives 1860-2000
Topics:
Medicine
Notes:
Abstract Thirty-two acutely psychotic, male schizophrenic patients received raclopride, at 2, 6, or 12 mg/day, or haloperidol, 15 mg/day for 4 weeks after randomized, double-blind assignment. Twenty-six patients, including 19 who had been assigned one of the three doses of raclopride, completed the study. Raclopride, particularly at 12 mg/day, increased CSF homovanillic acid (HVA) at 4 weeks, and plasma HVA at 2 days, of treatment. The clinical response to raclopride was significantly correlated with plasma raclopride concentrations and baseline plasma HVA concentrations. Although raclopride is a substituted benzamide with atypical properties in animals, these results suggest that the doses of raclopride required for clinical efficacy and elevation of clinical indices of brain dopamine turnover are similar.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1007/BF02245331
Permalink
